Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson's disease

Marianne Luinstra, Wijnand Rutgers, Teus van Laar, Floris Grasmeijer*, Anja Begeman, Valmira Isufi, Luc Steenhuis, Paul Hagedoorn, Anne de Boer, Henderik W. Frijlink

*Corresponding author voor dit werk

OnderzoeksoutputAcademicpeer review

13 Citaten (Scopus)
252 Downloads (Pure)

Samenvatting

Background: Inhaled levodopa may quickly resolve off periods in Parkinson's disease. Our aim was to determine the pharmacokinetics and tolerability of a new levodopa dry-powder inhaler. Methods: A single-centre, single-ascending, single-dose-response study was performed. Over three visits, eight Parkinson's disease patients (not in the 'off state') received by inhalation 30 mg or 60 mg levodopa, or their regular oral levodopa. Maximum levodopa plasma concentration (C-max), time to maximum plasma concentration (T-max) and area under the concentration time curve 0-180 min were determined. Spirometry was performed three times at each visit. Results: After inhalation, levodopa T-max occurred within 15 min in all participants, whereas after oral administration, T-max ranged from 20 min to 90 min. The bioavailability of inhaled levodopa without carboxylase inhibitor was 53% relative to oral levodopa with carboxylase inhibitor. No change in lung-function parameters was observed and none of the patients experienced cough or dyspnoea. No correlation was observed between inhalation parameters and levodopa pharmacokinetic parameters. Conclusion: Inhaled levodopa is well tolerated, absorbed faster than oral levodopa, and can be robustly administered over a range of inhalation flow profiles. It therefore appears suitable for the treatment of off periods in Parkinson's disease.

Originele taal-2English
Aantal pagina's10
TijdschriftTherapeutic advances in chronic disease
Volume10
Vroegere onlinedatum21-jun.-2019
DOI's
StatusPublished - 2019

Vingerafdruk

Duik in de onderzoeksthema's van 'Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson's disease'. Samen vormen ze een unieke vingerafdruk.

Citeer dit